IL2 and acute myeloid leukemia: Our differences in the current study are the use of random healthy unrelated donor NK cells for two doses in relapsed/refractory AML, conditioning regimen without total lymphoid irradiation (TLI) and to avoid Tregs stimulation subcutaneous IL2 administration was omitted.